TargetBeta
AVPR1A
arginine vasopressin receptor 1A · also AVPR1 · Arginine vasopressin and oxytocin receptors
1 program in company-led studies act on AVPR1A, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| SRX246rule | Azevan Pharmaceuticals | phase 2 | 71 running | – | ChEMBL |
Conditions their studies are in
- Anxiety Disorders, 1 program
- Disruptive, Impulse Control, and Conduct Disorders, 1 program
- Fragile X Syndrome, 1 program
- Huntington Disease, 1 program
- Stress Disorders, Post-Traumatic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2027SRX246 · Azevan Pharmaceuticals · phase 2 · NCT07328529
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.